CME/CE

Guest: Hussein Tawbi, MD, PhD Guest: Paolo A. Ascierto, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Sapna Patel, MD Guest: John M. Kirkwood, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuv...

Guest: Hussein Tawbi, MD, PhD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adj...

Guest: Hussein Tawbi, MD, PhD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adj...

Guest: Paolo A. Ascierto, MD Guest: Hussein Tawbi, MD, PhD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Paolo A. Ascierto, MD Guest: Hussein Tawbi, MD, PhD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Paolo A. Ascierto, MD Guest: Hussein Tawbi, MD, PhD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Paolo A. Ascierto, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic se...

Guest: John M. Kirkwood, MD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuv...

Guest: John M. Kirkwood, MD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuv...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU Guest: Amy Mottl, MD, MPH Guest: Muthiah Vaduganathan, MD, MPH This three-part panel series explores how emerging evidence from the CONFIDENCE trial is shaping the future of cardio-kidney-metabolic (CKM) care. In Chapter 1, the experts discuss the additive benefits and safety of combining a nonsteroidal MRA and an SGLT2 inhibitor. Chapter 2 focuses on pat...

Guest: Reshma L. Mahtani, DO In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants will gain insights into optimal evidence-based treatment...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...

Guest: Ghayas Issa, MD Guest: Amir Fathi, MD This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews...